Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
101.80    -2.20 (-2.12%)
Bid:
103.00
Ask:
103.40
Spread: 0.40 (0.388%)
Market Cap: £166.89m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

12 May 2011 07:00

RNS Number : 4433G
Yule Catto & Co PLC
12 May 2011
 



12 May 2011

 

Yule Catto & Co plc (the "Group") 

 

Interim Management Statement

 

At this afternoon's AGM of Yule Catto & Co plc, the international producer of speciality chemicals, Chairman Peter Wood will make the following statement which also comprises the Group's interim management statement for the period 1 January 2011 to date.

 

The Group's earnings for the first quarter were well ahead of the same period last year excluding any impact of the PolymerLatex acquisition, and the Board's expectations for financial performance for 2011 remain unchanged.

 

Overall demand in Yule Catto's Polymer business was solid. Asian demand was strong through the quarter, whilst Europe firmed after a slow start in the UK. Ongoing very substantial monomer price increases have had to be passed on to customers, resulting in the usual temporary margin compression as the increases are recovered and target unit margins per tonne restored. Consequently, although volumes increased in Polymers and turnover was strongly ahead, operating profit was flat year on year in the first quarter. Whilst Europe lagged the prior year, Asia was ahead, despite, as expected, profits being temporarily constrained by capacity during the quarter. This position will be resolved in the course of the second quarter with the new 15,000 tonne nitrile expansion coming on line and some spare capacity in the acquired PolymerLatex nitrile assets. In April, the existing Yule Catto polymer business performed ahead of prior year.

 

The acquisition of PolymerLatex completed at the end of March as anticipated. Integration planning progressed through the first quarter and is now being implemented. Post acquisition, the synergy potential has been confirmed, and management remain highly confident that at least £20m of synergies will be delivered as disclosed at the time of the acquisition announcement and to the same timetable. Regular updates on progress in delivering these synergies will be provided to investors, with the first update to be delivered with the group's half year results in August. As at the date of this statement, actions taken to date have already delivered synergies with an annual run rate value of approximately £2m.

 

PolymerLatex itself traded comfortably ahead of last year in the first quarter, and this has continued through April. The business benefited from good demand in central Europe for latex and volume growth in its Malaysian nitrile facility. Plans are already being developed for very substantial increases in capacity in Asia for nitrile and SBR latex to be brought on line before the end of 2012.

 

In the Group's other businesses in the first quarter, the Pharma division performed well ahead of what was a very weak result in the same period last year, whilst William Blythe continued to grow profits strongly.

 

Net debt at the end of the quarter stood at £235m reflecting the impact of the acquisition of PolymerLatex, in line with the Group's forecasts at the time of the acquisition announcement.

 

- Ends -

 

ENQUIRIES:

 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

David Blackwood, Group Finance Director

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

John Olsen

Ian Payne

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLFFLFERILLIL
Date   Source Headline
17th May 20077:01 amRNSAGM Statement
15th May 20074:29 pmRNSAnnual Report and Accounts
20th Apr 20079:40 amRNSAnnual Information Update
19th Apr 200712:47 pmRNSHolding(s) in Company
10th Apr 20075:26 pmRNSDirectorate Change
29th Mar 20074:37 pmRNSHolding(s) in Company
22nd Mar 200712:30 pmRNSDirectorate Change
12th Mar 20071:05 pmRNSDirector/PDMR Shareholding
12th Mar 20071:00 pmRNSDirector/PDMR Shareholding
7th Mar 20077:01 amRNSFinal Results
6th Mar 20074:04 pmRNSHolding(s) in Company
20th Feb 20074:29 pmRNSNotice of Results
1st Feb 20074:23 pmRNSBlocklisting Interim Review
18th Dec 20062:08 pmRNSVoting Rights and Capital
15th Dec 20067:58 amRNSTrading Statement
4th Dec 200612:49 pmRNSBlocklisting Interim Review
12th Oct 200610:46 amRNSHolding(s) in Company
2nd Oct 20063:20 pmRNSDirector/PDMR Shareholding
8th Sep 20069:01 amRNSDirector/PDMR Shareholding
7th Sep 20067:01 amRNSInterim Results
21st Aug 20063:22 pmRNSNotice of Results
21st Aug 20062:41 pmRNSDirectorate Change
1st Aug 20062:51 pmRNSBlocklisting Interim Review
14th Jul 20063:51 pmRNSNew Chief Executive
7th Jun 200611:14 amRNSDirector/PDMR Shareholding
5th Jun 20067:00 amRNSDisposal of Reabrook Limited
1st Jun 20064:48 pmRNSBlocklisting Interim Review
25th May 20063:11 pmRNSDirector/PDMR Shareholding
25th May 20063:09 pmRNSDirector/PDMR Shareholding
18th May 20064:59 pmRNSResult of AGM
18th May 200612:00 pmRNSAGM Statement
3rd May 200612:28 pmRNSAnnual Information Update
18th Apr 20063:49 pmRNSAnnual Report and Accounts
13th Apr 200611:30 amRNSDirector/PDMR Shareholding
13th Apr 200611:28 amRNSDirector/PDMR Shareholding
21st Mar 200612:05 pmRNSDirector/PDMR Shareholding
16th Mar 20067:01 amRNSFinal Results
20th Feb 20063:44 pmRNSHolding(s) in Company
20th Feb 20062:00 pmRNSAppointment
9th Feb 200612:10 pmRNSNotice of Results
31st Jan 200610:00 amRNSAdditional Listing
30th Dec 200512:00 pmRNSWithdrawal from SO2 business
23rd Dec 200510:14 amRNSDirector/PDMR Shareholding
14th Dec 20057:00 amRNSPre-close Trading Statement
8th Dec 20051:29 pmRNSBlocklisting Interim Review
7th Dec 20058:42 amRNSSale of Autoclenz Limited
7th Dec 20057:01 amRNSAdmission to trading on AIM
6th Dec 20054:23 pmRNSDirector Declaration
6th Dec 20054:18 pmRNSDirectorate Change
2nd Dec 200510:07 amRNSSale of Autoclenz Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.